Company Overview and News
Mechelen, België; 20 juni 2018, 22.01 CET; gereglementeerde informatie - Galapagos NV (Euronext & NASDAQ: GLPG) kondigt een kapitaalverhoging aan als gevolg van de uitoefening van warrants.
Mechelen, Belgium; 20 June 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises.
There is no approved therapy that can completely cure autoimmune or inflammatory diseases. The development of new treatment technologies is ongoing. Meanwhile, it is difficult to control autoimmune diseases in the majority of patients. The newest class of medications to treat these diseases is janus kinase (“JAK”) inhibitors, which are providing patients a better treatment option. This class of therapies has generated significant interest due to their better efficacy compared to tumor necrosis factor (“TNF”) inhibitor therapies.
WFC WFCNP WFC.WS AMGN GILD INCY WFC.PRL GLPG WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN ABBV WFC.PRY WFC.PRX PFE WFC.PRW ABBV WFC.PRV
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested.
SGEN NKTR DCPH ATRS NVCR PTLA LOXO CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE BMY MOR EXEL BLUE XNCR INCY NBIX GLPG ABEO AKCA HCM HCM ADMS GSK JNCE MRK IONS NVS ABEOW ARRY
Crispr Therapeutics (NASDAQ:CRSP) is one of the three companies that specialises in CRISPR-Cas9 genome editing technique. All three companies had spectacular IPOs but presently Crispr Therapeutics is the only one that has retained the initial euphoria and has become a $3.472B company in less than three years. Yesterday the stock slumped ~20%. The slump apparently resulted from the company’s disclosure that the FDA placed a clinical hold on its IND for gene therapy candidate CTX001 for sickle cell disease (‘SCD).
NKTR MBIO KIN VRTX TXMD GILD AZN GLPG CRSP ARWR GLPG DRNA SAGE AZN ACRS NVS FPRX SNDX
FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme.
SGEN NKTR ATRS BLCM VRTX NVCR PTLA CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE RDUS BMY CALD MOR EXEL GILD BLUE XNCR SLDB NBIX CRSP GLPG ABEO HCM HCM ADMS GSK MRK IONS NVS ABEOW ARRY
Gilead Sciences, Inc. (GILD - Free Report) and Galapagos NV (GLPG - Free Report) announced that the phase II study, EQUATOR, on pipeline candidate, filgotinib achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16, as assessed by the American College of Rheumatology 20 percent improvement score (ACR20).
GILD GLPG ABBV ABBV
Gilead Sciences, based in Foster City, California, and its development partner Galapagos NV, headquartered in Mechelen, Belgium, announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis.
IPF (Idiopathic Pulmonary Fibrosis) is a debilitating and fatal lung disease with no cure, with a median survival of 3 years. Esbriet (pirfenidone) and Ofev (nintedanib) are IPF approved treatments.
My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received thus far.
SGEN SCD NKTR ATRS NVCR PTLA CORT ONCE BPMC HNCMF DVAX BIIB ALXN FCSC CELG GSK BLUE RDUS BMY EXEL BLUE XNCR SM NBIX GLPG ABEO HCM HCM ADMS GSK MRK IONS NVS ABEOW ARRY
Mechelen, België; 20 mei 2018; 20.30 uur CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigt publicatiemijlpalen aan over GLPG1690 in idiopathische pulmonaire fibrose (IPF). Naast het presenteren van drie abstracts over het medicijn in ontwikkeling GLPG1690 op de American Thoracic Society Meeting (ATS) van 18 tot 23 mei in San Diego, Californië, VS, kondigt Galapagos de publicatie aan van de FLORA Fase 2a-studieresultaten in de meest recente uitgave van The Lancet Respiratory Medicine.
Mechelen, Belgium; 20 May 2018; 20.30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces publication milestones on GLPG1690 in idiopathic pulmonary fibrosis (IPF). In addition to presenting three abstracts on investigational drug GLPG1690 at the American Thoracic Society Meeting (ATS) from 18 to 23 May in San Diego, California, USA, Galapagos announces the publication of the FLORA Phase 2a study results in the most recent issue of The Lancet Respiratory Medicine.
20h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
21h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...